Immunopathology and Infectious Disease

Virus-Specific Antibody, in the Absence of T Cells, Mediates Demyelination in Mice Infected with a Neurotropic Coronavirus

Taeg S. Kim* and Stanley Perlman*†
From the Interdisciplinary Program in Immunology* and the Departments of Pediatrics and Microbiology,† University of Iowa, Iowa City, Iowa

Mice infected with mouse hepatitis virus strain JHM develop an inflammatory demyelinating disease in the central nervous system with many similarities to human multiple sclerosis. The mouse disease is primarily immune-mediated because demyelination is not detected in JHM-infected mice lacking T or B cells but does occur after transfer of JHM-specific T cells. Although less is known about the ability of antibodies to mediate demyelination, the presence of oligoclónally expanded B cells and high concentrations of antibodies (against self or infectious agents) in the central nervous system of many multiple sclerosis patients suggests that antibodies may also contribute to myelin destruction. Here, we show that anti-JHM antibodies, in the absence of T or B cells, caused demyelination in JHM-infected mice. Anti-JHM antibody was detected adjacent to areas of demyelination, consistent with a direct interaction between antibody and infected cells. Demyelination was reduced by 85 to 90% in infected RAG1−/− mice lacking normal expression of activating Fc receptors (FcγRIIa) and by ~76% when complement was depleted by treatment with cobra venom factor. These data demonstrate that JHM-specific antibodies are sufficient to cause demyelination and that myelin destruction in the presence of anti-virus antibodies results from a combination of complement- and Fc receptor-dependent mechanisms. (Am J Pathol 2005, 166:801–809)

The human disease multiple sclerosis (MS) is an immune-mediated, chronic inflammatory disease manifested clinically by neurological deficits and histologically by multiple foci of demyelination. T cells are detected in active demyelinating lesions and a critical role for these cells in demyelination has been clearly demonstrated in several animal models of demyelination, including rodents with experimental autoimmune encephalitis (EAE) and mice infected with coronaviruses or Theiler’s murine encephalomyelitis virus.1–3 Mice infected with the neurotropic JHM strain of mouse hepatitis virus (JHM) develop acute and chronic demyelinating diseases. We and others4–6 have shown that demyelination was not detected in JHM-infected mice lacking T and B cells [either mice with severe combined immunodeficiency or mice lacking functional recombination activating enzyme 1 (RAG1−/−)]. However, adoptive transfer of syngeneic splenocytes from JHM-immune mice resulted in rapid and reproducible demyelination.6,7 Depletion of T cells abrogated demyelination showing that T cells were necessary and B or other splenic cells were not sufficient for demyelination to occur. Either CD8 or CD4 T cells, in the absence of the other subset, were able to mediate demyelination in this model.4 In these experiments, T cells were transferred into RAG1−/− mice 4 days after they were immunized with JHM. The innate immune system was activated by JHM infection before T-cell transfer, as shown by up-regulated expression of several proinflammatory cytokines and chemokines, such as tumor necrosis factor-α, MIP-2, CCL7 (MCP-3), CCL4 (MIP-1β), CCL2 (MCP-1), CXCR10 (IP-10), and CCL5 (RANTES) in the central nervous system (CNS).8 This intense inflammatory milieu is likely critical for the rapid recruitment and activation of T cells to the CNS after adoptive transfer.

Less is known about the role of humoral immune factors in MS, but several features suggest that B cells or antibodies are involved in myelin destruction.9 Oligoclónal expansion of B cells is observed in the cerebrospinal fluid of patients with MS. Also, high levels of immunoglobulin are detected in the cerebrospinal fluid.10 Some of these cerebrospinal fluid-derived antibodies are directed against myelin proteins and pathogens such as Epstein-Barr virus11 and varicella-zoster virus.12 In addi-
tion, circulating antibodies against myelin proteins are detected in patients with MS\textsuperscript{13,14} and are a marker for the subsequent development of MS in patients with single episodes of a first neurological event.\textsuperscript{15} Furthermore, depositions of IgG and complement have been detected at sites of active demyelination in these patients.\textsuperscript{16} Multiple studies using rodent models of EAE also indicate that antibodies may have an important role in the demyelinating process. In mice, rats, and marmosets, treatment with antibody directed against an epitope of myelin oligodendrocyte glycoprotein resulted in the rapid onset of demyelination.\textsuperscript{17} Antibody was detected at sites of myelin destruction.\textsuperscript{13,18} The mechanism of antibody-mediated demyelination is not known with certainty. Several studies showed that complement depletion with cobra venom factor (CVF) resulted in delayed onset of EAE and studies showed that complement depletion with cobra venom factor (CVF) resulted in delayed onset of EAE and as a consequence, this model is sufficient to mediate demyelination.

**Pathogen-free RAG\textsuperscript{1−/−} mice** were purchased from Jackson Laboratories (Bar Harbor, ME) and bred at the University of Iowa (Iowa City, IA). FcR\textsuperscript{γ−/−} mice (B6x129; a generous gift from Dr. Timothy Ratliff, University of Iowa) were bred with RAG\textsuperscript{1−/−} mice to generate FcR\textsuperscript{γ−/−}RAG\textsuperscript{1−/−} mice. As a control group for experiments using FcR\textsuperscript{γ−/−}RAG\textsuperscript{1−/−} mice, age-matched littermates that were heterozygous for the FcR\textsuperscript{γ−/−} were used (FcR\textsuperscript{γ−/−}RAG\textsuperscript{1−/−}). Six- to eight-week-old animals were used for all studies. All animal studies were approved by the University of Iowa Animal Care and Use Committee.

**Induction of Demyelination**

RAG\textsuperscript{1−/−} mice were inoculated intracerebrally with 1000 plaque forming units (PFU) of the attenuated J2.2-V-1 strain of JHM (a generous gift from Dr. J. Fleming, University of Wisconsin, Madison, WI) in 30 μl of Dulbecco’s modified Eagle’s medium. Four days later, antibody was delivered intraperitoneally in 500 μl of sterile phosphate-buffered saline (PBS). Rabbit polyclonal anti-JHM antibody was prepared as described previously.\textsuperscript{27} The neutralizing titer (NT) of this antibody was 1:1862 plaque reduction units (PRD)/ml. Monoclonal antibodies (mAbs) used in these experiments include: 5B19.2 [anti-surface (S) glycoprotein; IgG1; NT: 1:2410 PRD/mg], 5A13.5 (anti-S; IgG2a, NT: 1:6230 PRD/mg), 5B188.2 [anti-nucleocapsid (N) protein, IgG2a, NT <1:100], 5B93.9 (anti-S; IgA, NT: <1:100\textsuperscript{28}), and 5B11.5 [anti-transmembrane (M) protein, IgG2a, NT: <1:100\textsuperscript{29}] all provided by Dr. M. Buchmeier, Scripps Research Institute, La Jolla, CA, and irrelevant antibody [anti-keyhole limpet hemocyanin (KLH), IgG1, Sigma, St. Louis, MO]. In preliminary experiments, we determined that 5 μg of mAb 5B19.2 administered intraperitoneally 4 days after infection resulted in maximum demyelination. Consequently, 5 μg of mAb per mouse were administered except where noted below. In some experiments, adoptive transfer of splenocytes from B6 mice previously immunized intraperitoneally with JHM to infected RAG\textsuperscript{1−/−} mice was performed as previously described.\textsuperscript{7}

**Virus Titration**

Virus was titered as described previously.\textsuperscript{27} Briefly, animals were sacrificed and perfused with sterile PBS. The tissues were homogenized in 6 ml of PBS. After two cycles of freeze-thawing, supernatants were obtained by centrifugation at 800 × g for 5 minutes at 4°C. Supernatants were assayed for virus by plaque assay on HeLa cells expressing the cellular receptor for mouse hepatitis virus (HeLa-MHVR). Viral titers are represented as PFU/g of brain ± SEM.

**Complement Depletion in Vivo**

To deplete complement in vivo, CVF isolated from *Naja naja kaouthia* (0.5 μg/kg; Calbiochem, La Jolla, CA) was administered intraperitoneally in 200 μl of PBS beginning 1 day before antibody injection (3 days after infection with
compared to recipients of anti-KLH mAb.

Results

**RAG1<sup>−/−</sup> Mice Infected with JHM Developed Demyelination after Infusion of Virus-Specific Antibody**

Initially, we investigated whether polyclonal rabbit anti-JHM antibody could mediate demyelination in JHM-infected RAG1<sup>−/−</sup> mice. JHM-infected RAG1<sup>−/−</sup> mice survive for 13 to 18 days after inoculation but do not develop significant levels of demyelination. In preliminary experiments, we determined that 50 μl of a rabbit polyclonal antibody delivered intraperitoneally at 4 days after infection resulted in a significant amount of demyelination whereas administration of normal rabbit sera did not (Table 1 and Figure 1, A and D). Anti-JHM but not normal rabbit sera prolonged survival. Because mice receiving normal sera developed symptoms of severe encephalitis (hunching, lethargy, ruffled fur) by 14 to 16 days after infection, we euthanized all mice at this time. We detected 12.4 ± 2.0% demyelination in mice receiving anti-JHM sera, with 1.9 ± 1.0% detected in recipients of normal rabbit sera (P < 0.002). Demyelination was significantly different in recipients of mAb 5B19.2 (P < 0.002), mAb 5A13.5 (P < 0.03), or mAb 5B11.5 (P < 0.02) when compared to recipients of anti-KLH mAb.

Statistics

A two-tailed unpaired Student’s t-test was used to analyze differences in mean values between groups.
tion was a consequence of virus clearance. To begin to understand the mechanism of antibody-induced demyelination, we examined spinal cord sections from antibody-treated, infected RAG1\(^{-/-}\) mice for antibody deposition. We were unable to detect antibody in the CNS of mice that received 50 \(\mu\)l of antibody. However, demyelination was also detected in mice that received 500 \(\mu\)l of rabbit anti-JHM antibody and we were able to detect...
We determined whether the amount of mAb 19.2 present in the serum of RAG1−/− mice was similar to levels of anti-JHM antibody detected in JHM-infected B6 mice. By comparison, JHM-infected RAG1−/− recipients of JHM-immune splenocytes exhibited similar amounts of demyelination, although the kinetics of myelin destruction was more rapid, with demyelination detected by 7 to 8 days after infection (Figure 2).5,7 Demyelination in mAb 5B19.2-treated mice did not reflect differences in virus clearance because similar amounts of virus were detected in recipients of anti-JHM mAb, PBS, or irrelevant antibody (Table 1). This inability to detect a difference in virus titer, in the presence of prolonged survival, may reflect a transient reduction in virus titer at early times after infection.

As expected, histological examination of sections from mAb 5B19.2-treated mice revealed the presence of activated macrophages/microglia adjacent to demyelinated areas (data not shown). To quantify the number of macrophages/microglia after antibody transfer, we counted the number of macrophages/microglia per mm²-wide cross-sections at 10 levels within spinal cords from three mice that received either mAb 5B19.2 or irrelevant antibody. In these experiments, all of the F4/80+ cells in 1.25-mm-wide cross-sections at 10 levels within spinal cords were counted. The number of macrophages/microglia present per cross-sectional area increased threefold after infusion of anti-JHM antibody compared to those that received control antibody (66.7 ± 3.7 versus 23.3 ± 2.9, P < 0.001). These additional infiltrating F4/80+ cells were localized entirely to the white matter. In other models, JHM-induced demyelination was primary and not secondary to axonal damage. Similarly, demyelination induced by anti-JHM antibody was primary, because intact axons were detected traversing areas of demyelination (Figure 1, K and L).

To examine whether the induction of demyelination after antibody transfer was unique to mAb 5B19.2, four additional mAbs were analyzed: mAb 5A13.5 (anti-S), mAb 5B93.9 (anti-N), mAb 5B11.5 (anti-M), and mAb 5B188.2 (anti-N) (Table 1). None of these antibodies, regardless of their specificity, exhibited a protective effect because all mice were moribund by 14 to 16 days after infection, when 5 μg were administered. This result was not expected, because mAb 5A13.5 has a high neutralizing antibody titer (1:6230 PRD/mg) and has been reported to protect B6 mice from encephalitis.29 We found, however, that mAb 5A13.5 was inefficient compared to mAb 5B19.2 at protecting B6 mice from acute encephalitis after inoculation with neurovirulent JHM (data not shown). Mice that received 5 μg of mAb 5A13.5 showed clinical signs of demyelination, including difficulty righting and hindlimb paresis, with demyelination detected on histological examination (6.0 ± 2.4%). This was within the range of demyelination observed in mice treated with mAb 5B19.2 and harvested at the same time after infection. Increasing the amount of mAb 5A13.5 administered from 5 to 30 μg prolonged mouse survival up to 20 days after infection and resulted in clinical outcomes and amounts of demyelination (22.5 ± 5.6%,
Table 2. Role of FcR and Complement in Antibody-Mediated Demyelination

<table>
<thead>
<tr>
<th>Animals</th>
<th>Number of mice</th>
<th>Days after infection</th>
<th>% Demyelination (mean ± SEM)</th>
<th>Viral titers (log_{10} PFU/g brain)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>FcRγ^+/−RAG1^-/-</td>
<td>6</td>
<td>17</td>
<td>9.1 ± 1.4^†</td>
<td>5.9 ± 0.1</td>
</tr>
<tr>
<td>FcRγ^+/−RAG1^-/-</td>
<td>9</td>
<td>17</td>
<td>1.2 ± 0.4^†</td>
<td>6.0 ± 0.1</td>
</tr>
<tr>
<td>RAG1^-/- + CVF</td>
<td>6</td>
<td>18-20</td>
<td>5.8 ± 1.9^†</td>
<td>6.0 ± 0.1^‡</td>
</tr>
<tr>
<td>RAG1^-/- + PBS</td>
<td>5</td>
<td>18-20</td>
<td>24.1 ± 4.9^†</td>
<td>5.5 ± 0.2^§</td>
</tr>
</tbody>
</table>

Mice were treated with 5 μg of anti-MHV S mAb (mAb 5B19.2) at 4 days after infection.

*Values are shown as mean ± SEM.

^†FcRγ^+/−RAG1^-/- mice had significantly more demyelination than FcRγ^+/−RAG1^-/- mice (P < 0.0001).

^‡CVF-treated mice had significantly less demyelination and significantly higher virus titers than control mice (P < 0.02 and P < 0.01, respectively).

n = 8) indistinguishable from those of mice treated with mAb 5B19.2 and also harvested at 18 to 20 days after infection.

Another anti-S antibody, mAb 5B93.9, which was not neutralizing in vitro, did not mediate demyelination. The single anti-M antibody that we analyzed also mediated demyelination in infected RAG1^-/- mice (Table 1). Although M protein is primarily an internal viral protein, at least one anti-M mAb has been shown to neutralize JHM infectivity in vitro and to protect mice from acute encephalitis, consistent with surface expression. At present, it is not known whether the epitope recognized by mAb 5B11.5 is exposed on the infected cell surface. Transfer of 5 μg of antibodies specific for either N or KLH to infected RAG1^-/-/ mice did not prolong survival or result in increased demyelination when compared to mice that received no antibody (Table 1). Thirty μg of anti-N antibody treatment, while not prolonging survival, resulted in demyelination in two of nine mice; this may reflect antibody access to nucleocapsid protein in some animals.

JHM-Infected RAG1^-/- Mice Deficient in Activating FcγRs Exhibited a Reduction in the Frequency and Amount of Demyelination

To begin to delineate the mechanism(s) of antibody-mediated demyelination, we first determined the role of activating FcγRs (FcγRII and FcγRIII) in this process. For this purpose, we generated FcRγ^+/−RAG1^-/- mice. These mice are deficient in FcγRI and FcγRIII expression, in addition to lacking T and B cells, and are therefore useful for investigating the role of FcR-dependent pathways in antibody-induced demyelination. FcRγ^+/− mice express ~20% as much FcγRI as wild-type mice, but no FcγRIII and exhibit impaired phagocytic function. In preliminary experiments, we observed that FcRγ^+/−/RAG1^-/- mice were slightly more resistant to JHM infection than RAG1^-/- mice, surviving 1 to 2 days longer, although no demyelination developed in any of these mice. This difference may reflect a difference in genetic lineage because FcRγ^+/− mice were obtained on a B6×129 background. Consequently, heterozygous littersmates were infected to control for potential genetic differences. FcRγ^+/−RAG1^-/- mice were more susceptible to JHM than were their FcRγ^+/−RAG1^-/- littersmates, with death occurring by 14.7 ± 1.5 days versus 17.0 ± 2.7 days after infection. The basis for this difference is not understood because no antibody is present in these animals. This enhanced susceptibility to JHM was even more evident after treatment with mAb 5B19.2, with FcRγ^+/−/RAG1^-/- mice moribund by 17 days after infection whereas JHM-infected FcRγ^+/−/RAG1^-/- mice survived for greater than 20 days after infection. All mice, therefore, were examined for viral load and demyelination in the CNS at 17 days after infection (Table 2). mAb 5B19.2-treated FcRγ^+/−/RAG1^-/- mice developed clinical signs of acute encephalitis such as hunching, lethargy, and ruffled fur by this time. In contrast, mAb 5B19.2-treated FcRγ^+/−/RAG1^-/- mice from the same litters exhibited primarily hindlimb weakness. Consistent with these clinical observations, demyelination in FcRγ^+/−/RAG1^-/- mice was significantly reduced compared to controls (9.1 ± 1.4% versus 12 ± 0.4%, P < 0.0001) (Table 2). These results were not explained by differences in virus titer because similar amounts of infectious virus were present in both FcRγ^+/−/RAG1^-/- and FcRγ^-/-/RAG1^-/- mice (Table 2).

Antibody-Mediated Demyelination Was Also Dependent on an Intact Complement Pathway

As described above, complement is a key component in rodent models of antibody-induced EAE. Additionally, recent studies showed that antibody-mediated autoimmune disease was dependent on both intact complement and FcR pathways for maximal disease expression. Consequently, we next evaluated the role of complement in anti-JHM antibody-induced demyelination, using CVF, a homolog of C3b, to deplete complement. Mice were treated with CVF at dosages and frequency shown previously to result in complement depletion (0.5 μg/kg beginning 1 day before antibody injection and every 3 days thereafter). CVF treatment in the presence of mAb 5B19.2 did not alter survival, with mice becoming moribund at 18 to 20 days after infection, similar to mice that received only antibody. However, mice treated with CVF showed clinical signs of encephalitis including hunching, lethargy, and ruffled fur, but few signs of demyelination (difficulty righting, hindlimb paresis) when compared to control mice. CVF treatment resulted in a slight increase in virus titer in the CNS (5.5 ± 0.2 log_{10} PFU/g brain versus 6.0 ± 0.1 log_{10} PFU/g brain, P < 0.02). Quantification of demyelination revealed a 76% reduction after CVF treatment compared to PBS-treated animals (24.1 ± 4.9% versus 5.8 ± 1.9%, P < 0.01) (Table 2). The amount of demyelination was greater in these experiments than in
Discussion

Previously, we and others showed that infusion of T cells into JHM-infected RAG1−/− or severe combined immunodeficiency mice resulted in demyelination.7,38 In this study, we extend these results to show that anti-JHM antibodies, in the absence of T cells, are also able to mediate demyelination in the same experimental system. Infusion of anti-KLH antibody or normal rabbit sera did not cause demyelination, showing that nonspecific binding to infected cells or to FcR on macrophages was inadequate to initiate this process. Furthermore, only some anti-virus antibodies were able to mediate demyelination. We cannot draw firm conclusions about the characteristics of anti-virus antibodies that allow them to mediate demyelination because only a limited number were examined in our study. It is likely that the viral epitopes recognized by demyelinating antibodies must be expressed on the cell surface although this has not been formally proven for mAb 5B11.5, the anti-M mAb that was able to induce demyelination. One anti-S antibody, mAb 5B93.9, did not mediate demyelination. This mAb may not be demyelinating because it is an IgA antibody, or because the epitope that it recognizes is not fully accessible on the native S glycoprotein.

Antibody-induced demyelination did not occur only after infection with the neuroattenuated J2.2 variant of JHM used in this study. Robust demyelination occurred in anti-JHM antibody-treated RAG1−/− mice intranasally infected with 5 × 104 PFU of the parental neurovirulent JHM strain. In this instance, a larger amount of antibody (10 μg of mAb 5B19.2) was required to enhance survival, but demyelination (32.3 ± 5.2%, n = 7) was observed at 13 to 20 days after infection. In addition, Matthews and colleagues39 showed that the A59 strain of mouse hepatitis virus also induced substantial amounts of demyelination when RAG1−/− mice were infected in the presence of virus-specific hyperimmune serum.

Antibodies capable of initiating myelin destruction may function by one or more mechanisms. Virus-specific antibody may directly interact with infected cells in the CNS, thereby resulting in the expression of chemoattractants for macrophages/microglia. Consistent with this possibility, anti-JHM antibody was detected at sites of demyelination (Figure 1H). CCL2/monocyte chemotactic protein-1 and CCL3/macrophage inflammatory protein-1α have been identified as crucial for macrophage/microglia infiltration in EAE40–42 and CCL2 and CCL5/RANTES were implicated in macrophage infiltration into the JHM-infected CNS.43,44 However, these chemokines are expressed at high levels in the JHM-infected RAG1−/− CNS8 and we have been unable to detect differences in expression of these chemokines after T-cell transfer that correlate with extent of demyelination.45,46 Thus, if these chemokines are important in antibody-mediated demyelination, it is likely that there will be localized differences in expression, rather than substantial changes in total production in the CNS. Alternatively, antibody may bind to circulating virus antigen and the resulting immune complexes may activate macrophages in the periphery. Because the milieu of the JHM-infected RAG1−/− CNS is proinflammatory,8 this peripheral activation may be all that is required for demyelination to occur. Precedent for this comes from EAE studies, because peripheral activation of macrophages is critical in the development of disease.47

Both complement and FcγR-dependent pathways were implicated in antibody-mediated demyelination in JHM-infected RAG1−/− mice, at least when mAb 5B19.2 was infused. mAb 5B19.2 is an IgG1 antibody, a subclass that activates complement poorly through the classical pathway. It is conceivable that the relative contribution of each pathway to demyelination would change if an antibody that was more effective in fixing complement were used. The role of complement in autoimmune disease, including EAE, remains controversial, partly because the effects of complement are pleiotropic. Some studies suggested that early components of the complement pathway were most critical. C3b and C4b may function as an opsonin for myelin, thereby enhancing phagocytosis by macrophages.48,49 C3a and C5a are chemoattractants for monocytes/macrophages29 and thereby may directly contribute to the influx of these cells into the white matter. Both of these complement products are anaphylatoxins and have multiple proinflammatory effects on macrophages, including enhancing differentiation and cytokine release.50 Additionally, C5a, via binding to C5aR, enhances the expression of activating FcγRs and diminishes that of FcγRIIb, an inhibitory FcγR.50 This property of C5a may contribute to the requirement for both complement- and FcγR-dependent pathways for maximal demyelination in JHM-infected mice. Other studies, using rodents deficient in C6 expression, suggest that formation of the MAC is critical for demyelination in antibody-mediated EAE. Demyelination and inflammatory cell infiltration were greatly reduced in C6−/− rats with EAE.22,23 MAC, by directly damaging infected oligodendrocytes, may contribute to an inflammatory cascade, resulting in macrophage infiltration and demyelination in JHM-infected mice. MAC, in sublytic amounts, may also contribute to inflammation by activating target cells.51

FcγRs were also critical for antibody-induced demyelination in JHM-infected RAG1−/− mice. Although FcγRs may be involved in antigen presentation,52 this function is unlikely to be important in RAG1−/− mice. More likely, macrophages/microglia are activated via the immunoreceptor tyrosine-based activation motif present on the γ chain of activating FcγRs. Activation via the FcγR may not only enhance recruitment of macrophages/microglia to the infected white matter, but also may be involved in release of cytokines including tumor necrosis factor-α and interleukin-1 and the release of substances such as oxygen radicals that may directly damage myelin.53

Requirements for both complement- and FcγR-dependent pathways have been demonstrated in other antibody-mediated pathological conditions, including immune complex-mediated skin and lung disease36,50 and
inflammatory arthritis. Collectively, these studies suggest that antibody binding to infected oligodendrocytes leads to generation of C3a and C5a and the formation of MAC as well as the activation of macrophages/microglia via FcR-dependent pathways. This results in increased migration of these cells into the white matter of the spinal cord with subsequent destruction of infected oligodendrocytes and myelin. Our results emphasize the multifactorial and complex nature of the demyelinating process. Although αβ T cells are generally responsible for the bulk of immune-mediated myelin damage in most experimental models, either γδ T cells or antibody directed against an antigen present in the CNS (JHM in our experiments) can also mediate demyelination. In patients with MS, T cells are also believed to be critical for the development of inflammation. However, IgG and complement deposition are detected in demyelinating lesions in MS lesions, consistent with a role in myelin destruction, and have also been implicated in the initial stages of the demyelinating process. Our results show that, under the appropriate circumstances, antibodies in the absence of T cells can cause demyelination.

Acknowledgments

We thank Dr. John Harty and Ajai Dandekar for critical review of the manuscript.

References


40. Mahad DJ, Ransohoff RM: The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003, 15:23–32


